Igc Pharma, INC 10-Q quarterly reports
Quarterly reports, with unaudited financial statements and management’s discussion of the quarter just ended.
AMEX
IGC Pharma reports Q1 2026 financial results, highlighting progress in its Phase 2 CALMA clinical trial for IGC-AD1 and ongoing AI platform development.
AMEX
IGC Pharma reported progress in its Phase 2 Alzheimer's trial and AI platform development, alongside a significant increase in cash and a reduced net loss for the six-month period, despite declining revenue.
AMEX
IGC Pharma reported a 33% reduction in net loss for Q1 2026, driven by increased revenue and operational efficiencies, while advancing its lead Alzheimer's drug candidate and AI diagnostic platform.
AMEX
IGC Pharma's Q3 2025 report reveals ongoing clinical trials for Alzheimer's treatment and a focus on revenue growth in its Life Sciences segment.
AMEX
IGC Pharma's Q2 2025 report highlights positive Phase 2 trial results for IGC-AD1, a potential treatment for agitation in Alzheimer's, alongside a financial update showing increased revenue and reduced operating losses.
AMEX
IGC Pharma's Q1 2025 report details financial results and progress in clinical trials for their Alzheimer's drug candidates, including IGC-AD1.
AMEX
IGC Pharma's Q3 2024 report details financial results and progress in clinical trials for their Alzheimer's drug candidates, including a Phase 2B trial for IGC-AD1.